Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apellis Pharmaceuticals Inc.

17.37
-0.6600-3.66%
Post-market: 17.400.0300+0.17%17:50 EDT
Volume:2.77M
Turnover:48.36M
Market Cap:2.18B
PE:-10.88
High:18.36
Open:18.22
Low:17.02
Close:18.03
Loading ...

Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics

Zacks
·
28 Feb

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Ahead of Upcoming Economic Data

MT Newswires Live
·
28 Feb

Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
28 Feb

BUZZ-Apellis rises after quarterly revenue beats estimates

Reuters
·
28 Feb

Apellis Pharmaceuticals Shares up 6.8% Premarket After Q4 Results

THOMSON REUTERS
·
28 Feb

Apellis Pharmaceuticals Q4 Net Loss Narrows, Revenue Rises

MT Newswires Live
·
28 Feb

Apellis Pharmaceuticals' Cash And Cash Equivalents Of $411.3M As Of December 31, 2024; Projected Revenues And Cash Expected To Be Sufficient To Fund Operations To Profitability

Benzinga
·
28 Feb

Earnings Flash (APLS) Apellis Pharmaceuticals Posts Q4 Net Loss $-0.29 a Share, vs. FactSet Est of $-0.37 Loss

MT Newswires Live
·
28 Feb

Stock Track | Apellis Pharmaceuticals Soars 9.62% Pre-Market on Revenue Growth Despite Q4 Loss

Stock Track
·
28 Feb

BRIEF-Apellis Pharmaceuticals Q4 Basic EPS USD -0.29

Reuters
·
28 Feb

Apellis Pharmaceuticals Q4 Product Revenue USD 191.172 Million

THOMSON REUTERS
·
28 Feb

Apellis Pharmaceuticals Q4 Basic EPS USD -0.29

THOMSON REUTERS
·
28 Feb

Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks
·
25 Feb

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire
·
24 Feb

Why Apellis Pharmaceuticals, Inc. (APLS) is the Most Oversold Pharma Stock to Buy According to Analysts

Insider Monkey
·
24 Feb

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks
·
21 Feb

High Growth Tech Stocks In The United States To Watch

Simply Wall St.
·
21 Feb

Apellis announces EMA validation of Aspaveli indication extension application

TIPRANKS
·
20 Feb

Apellis Pharmaceuticals, Sobi Say EMA Validated Indication Extension Application for Potential Kidney Disease Treatment

MT Newswires Live
·
20 Feb

Apellis and Sobi Announce Ema Validation of Indication Extension Application for Aspaveli® (Pegcetacoplan) for C3g and Primary Ic-Mpgn

THOMSON REUTERS
·
20 Feb